Vaccine News and Research RSS Feed - Vaccine News and Research

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
New discovery could help efforts to produce more effective vaccines

New discovery could help efforts to produce more effective vaccines

The best defense is a good offense, especially when it comes to the immune system. The troops that respond to an infection are split into two squadrons, and, until recently, it seemed that the two were independent, without much interaction. [More]
FDA approves use of Menactra for booster vaccination against meningococcal disease

FDA approves use of Menactra for booster vaccination against meningococcal disease

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age. [More]
Canada funds 22 inventive ideas for improving health in low-resource countries

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries. [More]
New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. [More]
Hospitals can improve flu vaccination rate among health care workers by using mandatory policy

Hospitals can improve flu vaccination rate among health care workers by using mandatory policy

Hospitals can greatly improve their flu vaccination rate among health care workers by using a mandatory employee vaccination policy, according to a Henry Ford Health System study. [More]
Scientists identify how immune cells use two critical receptors to clear dead cells from the body

Scientists identify how immune cells use two critical receptors to clear dead cells from the body

In most of the tissues of the body, specialized immune cells are entrusted with the task of engulfing the billions of dead cells that are generated every day. [More]
Viewpoints: End-of-life discussions; seniors missing their vaccinations; health law's new political calculations

Viewpoints: End-of-life discussions; seniors missing their vaccinations; health law's new political calculations

There is reason to hope that a degree of sanity may be returning to the touchy issue of advance planning for medical care at the end of life. [More]
Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin). [More]
61% less cases of genital warts among women after introducing HPV vaccination program

61% less cases of genital warts among women after introducing HPV vaccination program

GPs in Australia are managing 61 per cent less cases of genital warts among young women since the introduction of the national human papillomavirus (HPV) vaccination program, a new study from the University of Sydney reveals. [More]
Peramivir drug safe, effective at alleviating influenza symptoms

Peramivir drug safe, effective at alleviating influenza symptoms

An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms. [More]
New antibody in HIV-infected person binds to virus

New antibody in HIV-infected person binds to virus

An NIH-led team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment could exploit. [More]
Legatum Foundation donates $150,000 to Ebola Crisis Fund

Legatum Foundation donates $150,000 to Ebola Crisis Fund

The Legatum Foundation, the development arm of the Legatum Group, today announced a donation of $150,000 to the Ebola Crisis Fund, a fund established to help prevent the spread of the deadly Ebola virus in West Africa. [More]
Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model. [More]
Cepheid releases Xpert Flu/RSV XC for accurate determination of Flu A, Flu B and RSV infection

Cepheid releases Xpert Flu/RSV XC for accurate determination of Flu A, Flu B and RSV infection

Cepheid announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection. [More]
New vaccine in bid to move away from needles and syringes to skin delivery procedures

New vaccine in bid to move away from needles and syringes to skin delivery procedures

Drug delivery technologies that improve access and overall efficacy are becoming an essential part of the entire drug development process. [More]
‘Concerning’ rise in pneumococcus risk factors

‘Concerning’ rise in pneumococcus risk factors

Researchers report that the incidence of Streptococcus pneumoniae infection has fallen significantly in the USA in the past decade but describe a “concerning trend” whereby the baseline health status of those with serious pneumococcal disease has worsened. [More]
Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

Blend of three monoclonal antibodies can protect monkeys against Ebola virus, says UTMB researcher

A leading U.S. Ebola researcher from the University of Texas Medical Branch at Galveston has gone on record stating that a blend of three monoclonal antibodies can completely protect monkeys against a lethal dose of Ebola virus up to 5 days after infection, at a time when the disease is severe. [More]
Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014. [More]

NIH to begin trials for experimental Ebola vaccine

The announcement about the testing comes as the outbreak in West Africa grows. The World Health Organizations says it could have infected more than 20,000 people. [More]
Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Researchers receive encouraging results from two historic pediatric HIV vaccine trials

Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s. [More]